ARS Pharmaceuticals (SPRY) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on ARS Pharmaceuticals (SPRY) is Neutral.

The composite score behind that read is -0.18, weighing +0.14 of bullish evidence against -0.28 bearish.

ARS Pharmaceuticals last closed at $4.29, +5.41% on the session.

Against the IVW growth benchmark the position is +4.49% over the forecast window.

The read is built from 11 underlying insights — 2 bullish and 9 bearish.

Agreement across those insights is 82%.

15 graded predictions for SPRY so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks ARS Pharmaceuticals in the 4th percentile on return on equity, where 100 is best.

ARS Pharmaceuticals is classified under Health Care / Biotechnology, with a market capitalisation of $404.75M.

StockMap tracks ARS Pharmaceuticals as the 177th largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite ARS Pharmaceuticals ranks 150th of 344 in the group, against a group median of -0.21.